Roivant Sciences Ltd (ROIV) Stock Price, Quote & News

Company Profile

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythemat...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7400 3347

Website: roivant.com

Address:

50 Broadway, 7th Floor, London, United Kingdom

LS172 Feb. 23 at 9:02 PM

$ROIV $ABUS Never thought that on a day when most of my stocks are in the red, ABUS and ROIV are keeping me in the green. 😀

0 · Reply

BrenFal0919 Feb. 22 at 3:46 AM

$ABUS not trying to pump I need more shares, but is there one stock with more upside potential then $ABUS & $ROIV with not much downside. We’re taking about a major major decision with billions of dollars at stake coming down in a few weeks or anyday with settlement’s. I mean come one who’s selling I have my tickets. With the recent decisions handed down it looks very very positive here !

1 · Reply

DonaldHubbard766 Feb. 21 at 8:50 AM

$ROIV Roivant Sciences incubates biotech platforms. Value driven by subsidiary progress. Capital allocation is key.

0 · Reply

DocPharm Feb. 20 at 2:19 AM

$ROIV hmmm ATH in AH too $ABUS

0 · Reply

DocPharm Feb. 18 at 1:13 PM

$ROIV still very much under the radar too $PFE has a friend in Roivant, though many overlook

0 · Reply

countingguy2006 Feb. 17 at 3:58 PM

$ABUS $ROIV In their "Seal The Parties’ Motion In Limine Papers" Moderna purposely bundled their argument in order to keep Arbutus, the Court and possible "competitors" from seeing their "proprietary" IP theft formulas, infringing processes and pricing models, so that they can keep stealing without paying royalties, license fees, interest and penalties to businesses for their work and IP. If a company like Moderna has a business model that exclusively uses IP of other companies and plays with legal formulas/IP proprietary processes to questionably make the technology work and create doubt, then this shows the company has no foresight or innovative talent to be successful without stealing. I hope their processes and the like gets out to the public without redaction, and that other companies take their work and financially benefit from it; the exact thing that they do to others.

4 · Reply

Eidmar Feb. 14 at 11:00 PM

$ROIV USPTO Director Squires Needs our Support. https://api.neonemails.com/emails/content/NohK02wuBH_0Bl_JRCeBSA-mkFxRHgF4nsu5f70P7O4=

0 · Reply

AlertsAndNews Feb. 14 at 9:53 PM

$ROIV Insider sells here. Pretty large too Keith S. Manchester (Director) sold 1,225,784 shares at an average price of $26.64 (Form 4). Daniel Allen Gold (Director) sold 1,225,784 shares at an average price of $26.64 (Form 4).

0 · Reply

countingguy2006 Feb. 11 at 3:15 PM

$ABUS $ROIV recent losses for $MRNA with the FDA, court rulings not in their favor, doubt about their decisions/ability to follow through in their pipeline aspirations and lack of favor in the court of public opinion...that called Karma!

0 · Reply

Quantumup Feb. 11 at 1:00 PM

Goldman Sachs⬆️ $ROIV's PT to $38 from $36 and reiterated at Buy. $UTHR $LQDA INSM GOSS IMVT ABUS Here's what Goldman Sachs said in its note: https://x.com/Quantumup1/status/2021569067983810866?s=20

0 · Reply

Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade)

Feb 6, 2026, 3:44 PM EST - 17 days ago

Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript

Feb 6, 2026, 7:00 AM EST - 17 days ago

Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Feb 6, 2026, 7:00 AM EST - 17 days ago

Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)

Feb 6, 2026, 7:00 AM EST - 17 days ago

Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

Jan 23, 2026, 4:15 PM EST - 4 weeks ago

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Jan 12, 2026, 10:15 PM EST - 6 weeks ago

Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P.

Jan 8, 2026, 10:42 AM EST - 6 weeks ago

Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript

Dec 22, 2025, 11:25 PM EST - 2 months ago

Goldman Sachs Mid Cap Growth Fund Q3 2025 Investment Update

ALAB RDDT URI

Dec 12, 2025, 6:12 PM EST - 2 months ago

Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript

Dec 11, 2025, 7:30 AM EST - 2 months ago

Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day

Nov 18, 2025, 2:28 PM EST - 3 months ago

Roivant Sciences Ltd. (ROIV) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 13, 2025, 7:28 AM EST - 3 months ago

Roivant Sciences: Brepocitinib And Roadmap Still Underpriced

Nov 11, 2025, 10:31 AM EST - 3 months ago

Roivant Sciences Ltd. (ROIV) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 10, 2025, 12:31 PM EST - 3 months ago

Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript

Nov 10, 2025, 7:00 AM EST - 3 months ago

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

Oct 27, 2025, 4:10 PM EDT - 4 months ago

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

IMVT

Oct 27, 2025, 4:10 PM EDT - 4 months ago

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Sep 25, 2025, 2:47 AM EDT - 5 months ago

Roivant Sciences Ltd. (ROIV) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 24, 2025, 10:57 PM EDT - 5 months ago

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 23, 2025, 5:45 AM EDT - 5 months ago

Roivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call Transcript

Sep 17, 2025, 3:43 PM EDT - 5 months ago

Roivant Sciences Ltd. - Special Call

Sep 17, 2025, 12:13 PM EDT - 5 months ago

Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial

Sep 17, 2025, 8:21 AM EDT - 5 months ago

Roivant, Priovant Therapeutics' rare skin and muscle disease drug shows promise in trial

Sep 17, 2025, 7:00 AM EDT - 5 months ago

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

Sep 11, 2025, 4:30 PM EDT - 5 months ago

Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List

Sep 8, 2025, 8:25 PM EDT - 6 months ago

Roivant Sciences Ltd. (ROIV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 7:00 AM EDT - 6 months ago

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Sep 3, 2025, 11:07 PM EDT - 6 months ago

Roivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-Of-Concept Study Remission Data Transcript

Sep 3, 2025, 1:01 PM EDT - 6 months ago

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Aug 15, 2025, 9:30 AM EDT - 6 months ago

Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack

Aug 11, 2025, 12:28 PM EDT - 7 months ago

Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript

Aug 11, 2025, 7:00 AM EDT - 7 months ago

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

Jul 28, 2025, 4:05 PM EDT - 7 months ago

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

Jun 16, 2025, 7:00 AM EDT - 9 months ago

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

Jun 9, 2025, 4:05 PM EDT - 9 months ago

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

May 29, 2025, 2:17 PM EDT - 9 months ago

Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call Transcript

May 29, 2025, 7:00 AM EDT - 9 months ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

May 15, 2025, 4:10 PM EDT - 10 months ago

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

Apr 23, 2025, 12:13 PM EDT - 10 months ago

Roivant Sciences: Primed For Growth With A De-Risked Pipeline

Apr 21, 2025, 7:00 AM EDT - 11 months ago

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

Mar 19, 2025, 7:45 AM EDT - 1 year ago

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Mar 18, 2025, 4:32 PM EDT - 1 year ago

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Mar 3, 2025, 9:15 AM EST - 1 year ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ABUS

Feb 10, 2025, 12:32 PM EST - 1 year ago

Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript

Feb 10, 2025, 7:00 AM EST - 1 year ago

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

Feb 5, 2025, 12:12 PM EST - 1 year ago

Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)

Feb 3, 2025, 7:00 AM EST - 1 year ago

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

Jan 29, 2025, 4:05 PM EST - 1 year ago

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and Development

LS172 Feb. 23 at 9:02 PM

$ROIV $ABUS Never thought that on a day when most of my stocks are in the red, ABUS and ROIV are keeping me in the green. 😀

0 · Reply

BrenFal0919 Feb. 22 at 3:46 AM

1 · Reply

DonaldHubbard766 Feb. 21 at 8:50 AM

$ROIV Roivant Sciences incubates biotech platforms. Value driven by subsidiary progress. Capital allocation is key.

0 · Reply

DocPharm Feb. 20 at 2:19 AM

$ROIV hmmm ATH in AH too $ABUS

0 · Reply

DocPharm Feb. 18 at 1:13 PM

$ROIV still very much under the radar too $PFE has a friend in Roivant, though many overlook

0 · Reply

countingguy2006 Feb. 17 at 3:58 PM

4 · Reply

Eidmar Feb. 14 at 11:00 PM

$ROIV USPTO Director Squires Needs our Support. https://api.neonemails.com/emails/content/NohK02wuBH_0Bl_JRCeBSA-mkFxRHgF4nsu5f70P7O4=

0 · Reply

AlertsAndNews Feb. 14 at 9:53 PM

0 · Reply

countingguy2006 Feb. 11 at 3:15 PM

0 · Reply

Quantumup Feb. 11 at 1:00 PM

0 · Reply

Godwins26 Feb. 11 at 6:29 AM

$QNCX $TCGL $ROIV $ANL $BNAI

0 · Reply

Godwins26 Feb. 11 at 6:28 AM

Lottery 🎰 Watchlist $QNCX is this the next lottery play and will you be rich 🤑 $TCGL $ROIV $ANL $BNAI

1 · Reply

Godwins26 Feb. 10 at 10:51 PM

Watchlist 😊 $QNCX $PLTR $ROIV $MOVE $PLRZ

0 · Reply

Bmdubb Feb. 10 at 3:28 PM

$ROIV pump it

0 · Reply

mikesterz7 Feb. 10 at 3:10 AM

$ROIV CSAMI-A mean change -22.3 at Week 16 (45 mg) 100% of 45 mg patients achieved ≥10-point CSAMI-A improvement 69% achieved two-point IGA improvement to Clear/Almost Clear 62% functional remission (CSAMI-A <5) in 45 mg arm Statistically significant separation vs placebo as early as Week 4 No serious adverse events; AEs mild or moderate

0 · Reply

DocPharm Feb. 10 at 2:54 AM

$ABUS the misinformation on reddit is crazy People please understand: $MRNA couldn’t just solve the issue by buying ABUS, because Genevant, a private company owned by $ROIV and ABUS, is the sole licensor. This dates WAY back to 2016 when a Canadian judge told MRNA to pound the metaphorical sand, for all but 4 indications. This was the same trial that gave $ALNY its rights to the same LNP for ONPATTRO. This was the same LNP that $BNTX licensed, outside of Covid (so far). ….Any redditors who would like to steal this and post it up, be my guest. You can even take full credit.

1 · Reply

DDRPOWER Feb. 10 at 1:15 AM

$ABUS on a side note: $ROIV is worth more than $MRNA

1 · Reply

NoBSPls Feb. 9 at 11:42 PM

$ROIV I own a lot of this. Wish I owned more. Go ROIV/ABUS

0 · Reply

Alfalcon Feb. 9 at 11:23 PM

$ROIV our dove finally outpaced $IMVT

0 · Reply

DocPharm Feb. 9 at 10:47 PM

$ROIV keep flying, my dove ❤️

1 · Reply

OfficialStocktwitsUser Feb. 9 at 10:26 PM

$ROIV RSI: 74.45, MACD: 0.6142 Vol: 1.51, MA20: 22.92, MA50: 22.11 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Godwins26 Feb. 9 at 9:22 PM

After hours Watchlist 😊 $TIRX 100Million volume incoming!!🚀 $ROIV $ABP $CCHH $BRLS

0 · Reply

Market Cap	19.43B
Revenue (ttm)	29.05M
Net Income (ttm)	-171.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-592.01%
Debt to Equity Ratio	0.00

Volume	4,414,900
Avg Vol	7,440,906
Day's Range	N/A - N/A
Shares Out	715.70M
Stochastic %K	89%
Beta	1.22
Analysts	Strong Sell
Price Target	$31.73